Prestige Consumer Healthcare (NYSE:PBH) Sets New 1-Year Low – Should You Sell?

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) reached a new 52-week low on Thursday . The company traded as low as $58.03 and last traded at $58.4410, with a volume of 333597 shares traded. The stock had previously closed at $59.18.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PBH shares. Jefferies Financial Group decreased their target price on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Wall Street Zen downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Oppenheimer decreased their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Price Performance

The firm has a fifty day moving average price of $61.94 and a two-hundred day moving average price of $71.98. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $2.81 billion, a P/E ratio of 13.72, a P/E/G ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare’s revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the company. Cerity Partners LLC lifted its position in Prestige Consumer Healthcare by 3.7% in the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock valued at $315,000 after acquiring an additional 132 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Prestige Consumer Healthcare by 11.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,304 shares of the company’s stock worth $1,058,000 after purchasing an additional 1,251 shares during the last quarter. Texas Yale Capital Corp. lifted its holdings in shares of Prestige Consumer Healthcare by 22.7% during the first quarter. Texas Yale Capital Corp. now owns 7,239 shares of the company’s stock valued at $622,000 after purchasing an additional 1,339 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Prestige Consumer Healthcare by 354.0% during the first quarter. XTX Topco Ltd now owns 22,778 shares of the company’s stock valued at $1,958,000 after purchasing an additional 17,761 shares in the last quarter. Finally, Pacific Capital Partners Ltd purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter valued at $1,075,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.